When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.

A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.

The diversified UK firm is betting $20m upfront and up to $150m total on a novel inferior vena cava filter technology.

MedLumics appointed James Greene as its CEO and Giovanni Leo to the board of directors. The Madrid-based company expects the two industry veterans to carry it through the its next phase of growth – commercialization of the AblaView AF catheter.